SchizophreniaNCT00278668
ECT Schizophrenia Serotonin Study
An observational study of Schizophrenia, run by Sha'ar Menashe Mental Health Center.
Trial summary
We suggest to investigate serotonin uptake in schizophrenia patients receiving ECT Read more about this study
- Who is it for?
- Ages 18 to 55 years
- Conditions the study is for
- Schizophrenia
- How many people
- 15 participants
- Where
- No sites listed yet
- Study dates
- Oct 2006to Oct 2006
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Participants must meet DSM-IV criteria for schizophrenia, as assessed by the Structured Clinical Interview - Patient Version (SCID) (First et al., 1995).
- Ages 18 -55 Men and/or women -
Who cannot join
- History of neurological disorders, active substance abuse in the previous 3 months.
- Estimated IQ less then 70.
- SSRIs treatment 4 weeks prior to the study.
- Any subject suffering from inflammatory fever disease will be excluded from the study.
- -
Trial locations and contacts
No sites are listed yet.
About this study
Official title: Serotonin Uptake to Lymphocytes and Citalopram Platelets Binding of Treatment-Resistant Schizophrenia Patients Before and After Electroconvulsive Therapy
We suggest to investigate serotonin uptake in schizophrenia patients receiving ECT
Read the detailed description
We suggest to investigate serotonin uptake in schizophrenia patients receiving ECT
- Conditions
- Schizophrenia
- Medical subject headings
- Schizophrenia
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jan 2006 (estimated)
- Study startOct 2006
- Study completionOct 2006 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SchizophreniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Time perspective
- Prospective
- Enrolment
- 15 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sha'ar Menashe Mental Health Center
- Sponsor type
- University, hospital or other
- Investigators
- Avi Peled, MD, Principal investigator, Shaar Menashe MHCIlan Modai, M.D. MHA, Principal investigator, Shaar MenasheMoshe Rehavi, Ph.D., Principal investigator, TAU
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00278668
- Sponsor's protocol ID
- 123.ctil
- Status last verified
- May 2008
- First submitted
- 16 Jan 2006
- Last updated
- 21 May 2008
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 May 2008. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Serotonin Uptake to Lymphocytes and Citalopram Platelets Binding of Treatment-Resistant Schizophrenia Patients Before and After Electroconvulsive Therapy
- ClinicalTrials.gov ID
- NCT00278668
- Acronym / sponsor ID
- 123.ctil
- Conditions
- Schizophrenia
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 15 participants (estimated)
- Lead sponsor
- Sha'ar Menashe Mental Health CenterUniversity, hospital or other
- Study start
- Oct 2006
- Study completion
- Oct 2006 (estimated)
- First posted
- 18 Jan 2006 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
We suggest to investigate serotonin uptake in schizophrenia patients receiving ECT
Detailed description
We suggest to investigate serotonin uptake in schizophrenia patients receiving ECT
Study design
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Participants must meet DSM-IV criteria for schizophrenia, as assessed by the Structured Clinical Interview - Patient Version (SCID) (First et al., 1995).
- Ages 18 -55 Men and/or women -
Key exclusion criteria (5 listed)
- History of neurological disorders, active substance abuse in the previous 3 months.
- Estimated IQ less then 70.
- SSRIs treatment 4 weeks prior to the study.
- Any subject suffering from inflammatory fever disease will be excluded from the study.
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 May 2008.
Related trials for Schizophrenia
RecruitingPhase 1
A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
Schizophrenia
Recruiting
A Relation Between Craving Induction and Treatment Response in Deep Transcranial Magnetic Stimulation (dTMS) for Reducing Antipsychotic-induced Weight Gain in Schizophrenia
Schizophrenia, Antipsychotic Induced Weight Gain
Recruiting
Impact of Cerebellar TMS on Brain and Cognitive Functions in Schizophrenia: a Pilot Study
Schizophrenia, Cerebellar Function
Recruiting
tACS for Working Memory in Schizophrenia
Schizophrenia, Working Memory
Recruiting
Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 3
Schizophrenia / Schizoaffective Disorder, SCHIZOPHRENIA 1 (Disorder)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Avi Peled, MD principal investigator
Shaar Menashe MHC
Ilan Modai, M.D. MHA principal investigator
Shaar Menashe
Moshe Rehavi, Ph.D. principal investigator
TAU
Questions about this trial
What is this clinical trial studying?
An observational study of Schizophrenia, run by Sha'ar Menashe Mental Health Center.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 21 May 2008. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Avi Peled, MD (972522844050, av_peled@netvision.net.il), or a site near the patient. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 May 2008.